

Anti-Treponema pallidum ELISA (IgM)

Test instruction











ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
EI 2111-9601 M	Treponema pallidum	IgM	Ag-coated microplate wells	96 x 01 (96)


Indication: The ELISA test kit provides a semiquantitative in vitro assay for human antibodies of the immunoglobulin class IgM against *Treponema pallidum* in serum or plasma for the diagnosis of infections with *Treponema pallidum*, associated diseases: Lues.

Application: The Anti-Treponema pallidum ELISA (IgM) is suitable as a confirmatory test in the framework of a 2-step strategy for the specific detection of *Treponema pallidum* infections, but can also be used as specific screening or exclusionary test.

Principle of the test: The test kit contains microtiter strips each with 8 break-off reagent wells coated with purified recombinant antigens of *Treponema pallidum*. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgM antibodies (also IgA and IgG) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgM (enzyme conjugate) catalysing a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells coated with antigens 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	
2. Calibrator (IgM, human), ready for use	dark red	1 x 2.0 ml	
3. Positive control (IgM, human), ready for use	blue	1 x 2.0 ml	
4. Negative control (IgM, human), ready for use	green	1 x 2.0 ml	
5. Enzyme conjugate peroxidase-labelled anti-human IgM (goat), ready for use	red	1 x 12 ml	
6. Sample buffer buffer containing IgG/RF-absorbent (anti-human IgG antibody preparation obtained from goat), ready for use	green	1 x 100 ml	
7. Wash buffer 10x concentrate	colourless	1 x 100 ml	
8. Chromogen/substrate solution TMB/H ₂ O ₂ , ready for use	colourless	1 x 12 ml	
9. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	
10. Protective foil	---	2 pieces	
11. Quality control certificate	---	1 protocol	
12. Test instruction	---	1 booklet	

 Lot description		 Storage temperature
 In vitro diagnostic medical device		

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents should be disposed of according to official regulations.



Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

The thermostat adjusted ELISA incubator must be set at +37°C ± 1°C.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.
- **Calibrator and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use. The green coloured sample buffer contains IgG/RF absorbent. Serum or plasma samples diluted with this sample buffer are only to be used for the determination of IgM antibodies.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallisation occurs in the concentrated buffer, warm it to +37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionised or distilled water (1 part reagent plus 9 parts distilled water).
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.
The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light ☼. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

Warning: The calibrator and controls of human origin have tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the agent sodium azide in a non-declarable concentration. Avoid skin contact.



Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Introduction: Before the determination of specific antibodies of class IgM, antibodies of class IgG should be removed from the patient sample. This procedure must be carried out in order to prevent any rheumatoid factors of class IgM from reacting with specifically bound IgG, which would lead to false positive IgM test results, and to prevent specific IgG displacing IgM from the antigen, which would lead to false IgM-negative test results.

Functional principle: The sample buffer (green coloured!) contains an anti-human antibody preparation from goat. IgG from a serum sample is bound with high specificity by these antibodies and precipitated. If the sample also contains rheumatoid factors, these will be absorbed by the IgG/anti-human IgG complex.

Separation properties:

- All IgG subclasses are bound and precipitated by the anti-human IgG antibodies.
- Human serum IgG in concentrations of up to 15 mg per ml are removed (average serum IgG concentration in adults: 12 mg per ml).
- Rheumatoid factors are also removed.
- The recovery rate of the IgM fraction is almost 100%.

Performance: The **patient samples** for analysis are diluted **1:101** with green coloured sample buffer. For example, add 10 µl sample to 1.0 ml sample buffer and mix well by vortexing. Sample pipettes are not suitable for mixing. Incubate the mixture for at least **10 minutes** at room temperature (+18°C to +25°C). Subsequently, it can be pipetted into the microplate wells according to the pipetting protocol.

Notes:

- Antibodies of the class IgG should not be analysed with this mixture.
- It is possible to check the efficacy of the IgG/RF absorbent for an individual patient sample by performing an IgG test in parallel to the IgM test using the mixture. If the IgG test is negative, the IgM result can be considered as reliable.
- The calibrator and controls are ready for use, do not dilute them.



Incubation

(Partly) manual test performance

Sample incubation: (1st step)

Transfer 100 µl of the calibrator, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol.

For manual processing of microplate wells, cover the finished test plate with the protective foil. When using an automated microplate processor for incubation follow the recommendations of the instrument manufacturer.

Incubate **60 minutes** at $+37^{\circ}\text{C} \pm 1^{\circ}\text{C}$.

Washing:

Manual: Remove the protective foil, empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.

Automatic: Remove the protective foil and wash the reagent wells 3 times with 450 µl of working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Mode").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid (> 10 µl) in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short residence times) can lead to false high extinction values.

Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation: (2nd step)

Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgM) into each of the microplate wells. Incubate for **30 minutes** at room temperature ($+18^{\circ}\text{C}$ to $+25^{\circ}\text{C}$).

Washing:

Empty the wells. Wash as described above.

Substrate incubation: (3rd step)

Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature ($+18^{\circ}\text{C}$ to $+25^{\circ}\text{C}$) (protect from direct sunlight).

Stopping:

Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:

Photometric measurement of the colour intensity should be made at a **wavelength of 450 nm** and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.



Test performance using fully automated analysis devices

Sample dilution and test performance are carried out fully automatically using an analysis device. The incubation conditions programmed in the respective software authorised by EUROIMMUN may deviate slightly from the specifications given in the ELISA test instruction. However, these conditions were validated in respect of the combination of the EUROIMMUN Analyzer I, Analyzer I-2P or the DSX from Dynex and this EUROIMMUN ELISA. Validation documents are available on enquiry.

Automated test performance using other fully automated, open-system analysis devices is possible. However, the combination should be validated by the user.

Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	C	P 6	P 14	P 22								
B	pos.	P 7	P 15	P 23								
C	neg.	P 8	P 16	P 24								
D	P 1	P 9	P 17									
E	P 2	P 10	P 18									
F	P 3	P 11	P 19									
G	P 4	P 12	P 20									
H	P 5	P 13	P 21									

The above pipetting protocol is an example of the **semiquantitative analysis** of antibodies in 24 patient samples (P 1 to P 24).

Calibrator (C), positive (pos.) and negative (neg.) control as well as the patient samples have been incubated in one well each. The reliability of the ELISA test can be improved by duplicate determinations of each sample.

The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimises reagent wastage.

Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

The extinction value of the calibrator defines the upper limit of the reference range of non-infected persons (**cut-off**) recommended by EUROIMMUN. Values above the indicated cut-off are to be considered as positive, those below as negative.

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator. Use the following formula to calculate the ratio:

$$\frac{\text{Extinction of the control or patient sample}}{\text{Extinction of calibrator}} = \text{Ratio}$$

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8:	negative
Ratio ≥0.8 to <1.1:	borderline
Ratio ≥1.1:	positive

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another, EUROIMMUN recommends retesting the samples.



A negative serological result does not exclude an infection. Particularly in the early phase of an infection, antibodies may not yet be present or are only present in such small quantities that they are not detectable. In case of a borderline result, a secure evaluation is not possible. If there is a clinical suspicion and a negative test result, we recommend clarification by means of other diagnostic methods and/or the serological investigation of a follow-up sample. A positive result indicates that there has been contact with the pathogen. In the determination of pathogen-specific IgM antibodies, polyclonal stimulation of the immune system or antibody persistence may affect the diagnostic relevance of positive findings. Significant titer increases (exceeding factor 2) and/or seroconversion in a follow-up sample taken after 7 to 10 days can indicate an acute infection. To investigate titer changes, sample and follow-up sample should be incubated in adjacent wells of the ELISA microplate within the same test run. For diagnosis, the clinical picture of the patient always needs to be taken into account along with the serological findings.

Test characteristics

Calibration: As no quantificated international reference serum exists for antibodies against *Treponema pallidum*, results are provided in the form of ratios which are a relative measure for the concentration of antibodies in the serum or plasma. The calibration is based on internal reference sera which were used in the evaluation of the test system. The international standard for Human Syphilis Serum; 1. International standard preparation SSI code number HS reacts with ratio 4.0.

For every group of tests performed, the extinction values of the calibrator and the ratio of the positive and negative controls must lie within the limits stated for the relevant test kit lot. A quality control certificate containing these reference values is included. If the values specified for the control sera are not achieved, the test results may be inaccurate and the test should be repeated.

The binding activity of the antibodies and the activity of the enzyme used are temperature-dependent. It is therefore recommended using a thermostat in all three incubation steps. The higher the room temperature (+18°C to +25°C) during the incubation steps, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrator is subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigens: The microplate wells were coated with a mixture of four antigens of *Treponema pallidum*: p15, p17, p47 and TmpA. The corresponding cDNAs were expressed in *E. coli* as recombinant antigens.

Detection limit: The lower detection limit is defined as the mean value of an analyte-free sample plus three times the standard deviation and is the smallest detectable antibody titer. The lower detection limit of the Anti-*Treponema pallidum* ELISA (IgM) is ratio 0.06.

Cross reactivity: The quality of the antigen used ensures a high specificity and sensitivity of the ELISA. Sera from patients with infections caused by various agents were investigated with the Anti-*Treponema pallidum* ELISA (IgM). This ELISA showed no cross reactivity.

Antibodies against	n	Anti- <i>Treponema pallidum</i> ELISA (IgM) positive
Borrelia burgdorferi	10	0%
CMV	8	0%
EBV-CA	10	0%
HSV-1/2	2	0%
Measles virus	10	0%
Mumps virus	9	0%
Parvovirus B19	7	0%
Rubella virus	10	0%
Toxoplasma gondii	10	0%
VZV	4	0%



Interference: Haemolytic, lipaemic and icteric samples showed no influence on the result up to a concentration of 10 mg/ml for haemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 samples. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

<i>Intra-assay variation, n = 20</i>		
Sample	Mean value (Ratio)	CV (%)
1	1.1	4.4
2	3.3	4.2
3	6.1	3.9

<i>Inter-assay variation, n = 4 x 6</i>		
Sample	Mean value (Ratio)	CV (%)
1	1.2	5.8
2	3.5	5.4
3	6.2	4.6

Sensitivity and specificity: 72 clinically pre-characterised patient samples (INSTAND and RfB) were investigated with the EUROIMMUN Anti-Treponema pallidum ELISA (IgM). The sensitivity amounted to 100%, with a specificity of 100%. Borderline results were not included in the calculation.

n = 72		INSTAND/RfB		
		positive	borderline	negative
EUROIMMUN Anti-Treponema pallidum ELISA (IgM)	positive	17	0	0
	borderline	0	1	0
	negative	0	1	53

The specificity of the Anti-Treponema pallidum ELISA (IgM) was evaluated in a study performed on 37 patient sera which were seropositive for rheumatoid factors. None of the 37 samples tested positive using the Anti-Treponema pallidum ELISA (IgM).

Reference range: The levels of the anti-Treponema pallidum antibodies (IgM) were analysed with this EUROIMMUN ELISA in a panel of 500 healthy blood donors. With a cut-off ratio of 1.0, 0.2% of the blood donors were anti-Treponema pallidum positive (IgM).

Limitations of the procedure

The test is not intended to be used for the determination of suitability for transfusion, transplantation or cell administration.

Clinical significance

Treponema pallidum pallidum is a helically wound bacteria of the Spirochaeta family. This family includes five genera: Borrelia, Spirochaeta, Cristispira, Treponema and Leptospira. Treponema pallidum is the causative agent of syphilis or lues, a chronic infectious disease. The subspecies T. pallidum endemicum causes venereal syphilis; T. pallidum pertenue leads to a non-venereal infection occurring in tropical regions called framboesia; T. pallidum carateum is the causative agent of Pinta.

In 1905 Fritz Schaudinn (German zoologist, 1871-1906) and Erich Hoffmann (German dermatologist, 1868-1959) at the Charité in Berlin were the first to detect the causative agent of syphilis under the microscope. Spirochaeta were first found in 1913 by the Japanese microbiologist and physician Noguchi Hideyo (1876-1928) in the brain tissue of a patient with progressive paralysis.

Syphilis is transmitted from human to human during sexual acts via the mucosa. Indirect transmission by blood transfusions and wounds is also possible. During pregnancy and at birth the baby can become infected by the mother (syphilis connata). Syphilis is a known risk factor for abortions and stillbirths.

The disease is divided into different stages, the number of which varies in literature, depending on the world region. In German-speaking regions four stages are differentiated (primary, secondary, tertiary and quaternary stage). In Asia and sometimes in the USA, stages three and four are combined into the



tertiary stage. The secondary stage has a wider meaning and is subdivided into an early latent and a late latent phase.

The early latent stage is described as seroreactive, asymptomatic and infectious (approx. one year after infection), while the late latent phase is characterised as seroreactive, asymptomatic and non-infectious (more than one year after infection). In Central Europe the infection is divided into the following four stages:

Primary stage: The *ulcus durum* (hard-edged ulcer) is characteristic of the primary lesion of the syphilis (stage I) and normally occurs 3 weeks after infection, developing at the place of entry of the pathogen (e.g. penis). It is a painless ulcer, which contains large quantities of the pathogen and is therefore highly contagious. Typically, the clearly defined fibrous or crusted erosion has a raised hard edge. The possible swelling of the regional lymph nodes is painless and the lymph nodes remain displaceable. From that time on, the disease can be diagnosed e.g. using the TPHA test (*Treponema pallidum* haemagglutination assay). After 2 to 6 weeks the ulcer heals leaving a scar. The infection generally persists and develops into stage II. **Secondary stage:** Approximately 8 weeks after the infection, the disease manifests itself with flu-like symptoms such as fever, fatigue or headache and joint pain. In addition to a generalised swelling of the lymph nodes, 90% of patients show local or generalised skin disorders, which are accompanied by weak or no itching. At first, light pink patches form, which further evolve into hard, coppery nodules (papules). In the foreground are condylomata lata, broad papules which mainly affect skin folds. The liquid excreted by open and weeping papules is highly contagious. Additionally, various organ disorders may develop, for example, keratitis, iritis, hepatitis, vasculitis, and myocardial disorders.

All skin disorders (syphilids) heal after approximately 4 months. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years.

Tertiary stage: Typical manifestations of a *Treponema pallidum* infection in stage III are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, including gummatous and interstitial inflammation, perivasculitis, cardiovascular syphilis, neurosyphilis (asymptomatic and symptomatic form), osteitis, and periosteitis.

Quaternary stage: Ten to thirty years after an untreated infection, 8% to 10% of patients experience severe neurological disorders such as neurosyphilis with progressive paralysis and Tabes dorsalis with severe mental and vegetative disorders.

The **diagnosis** of syphilis is based on clinical findings according to the disease stage, microscopic detection of the infectious agent (dark field), and the serological detection of antibodies against *Treponema pallidum*.

Treponema pallidum pallidum has a length of 5 to 15 μm and a width of 0.2 μm with 10 to 20 turns and can rotate around its longitudinal axis. Due to its fine structure, it is difficult to make it visible under the microscope by staining. However, living bacteria can be investigated using dark field microscopy. Detection in cultures has not yet been achieved.

The TPHA (*Treponema pallidum* haemagglutination assay) is an assay for the indirect determination of antibodies against *Treponema pallidum*. Erythrocytes marked with proteins and polysaccharides of *Treponema pallidum* on their surface are mixed with patient serum. The presence of antibodies against *Treponema pallidum* in the patient serum causes agglutination of the erythrocytes (haemagglutination), which is visible to the naked eye.

When this screening test is positive, further serological investigation is recommended to confirm the result, either using the Anti-*Treponema pallidum* FTA-Abs Test or using state-of-the-art procedures such as the Anti-*Treponema pallidum* ELISA or the Anti-*Treponema pallidum* Westernblot (e.g. Anti-*Treponema pallidum* EUROLINE-WB). Antibodies against cardiolipin serve as an activity marker of the infection (VDRL or RPR test, EUROLINE WB).

Antibodies against *Treponema pallidum* can be detected in serum and in CSF. This is diagnostically relevant, for example, in children with congenital syphilis. For the quantitative *in vitro* detection of human antibodies of immunoglobulin class IgG against *Treponema pallidum* in CSF, the same ELISA as used for the determination of antibodies against *Treponema pallidum* in serum is suitable. When determining an infection of the CNS it is necessary to differentiate between intrathecally produced antibodies and antibodies which have migrated from the blood into CSF.



The intrathecal pathogen-specific antibody production is defined by the relative CSF/serum quotient CSQrel (synonym: antibody specificity index). The quotient is calculated from the ratio of agent-specific antibodies to total IgG in CSF in proportion to the ratio of agent-specific antibodies to total IgG in serum. With this method a *Treponema pallidum* infection in the CNS can be easily and reliably determined.

Literature references

1. Brown DL, Frank JE. **Diagnosis and management of syphilis.** Am Fam Physician 68 (2003) 283-290.
2. Centurion-Lara A, Molini BJ, Godornes C, Sun E, Hevner K, Van Voorhis WC, Lukehart SA. **Molecular differentiation of *Treponema pallidum* subspecies.** J Clin Microbiol 44 (2006) 3377-3380.
3. Dang Q, Feng J, Lu X, Zhang X, Xu H, Liu C, Nu X. **Evaluation of specific antibodies for early diagnosis and management of syphilis.** Int J Dermatol 45 (2006) 1169-1171.
4. Department of Health and Human Services. CDC. **Syphilis – Physician’s Pocket Guide.** www.cdc.gov/std/see/.
5. EUROIMMUN AG. **Testkit für die Labordiagnostik.** Deutsches Gebrauchsmuster DE 20 2012 004 404 (angemeldet 2012).
6. Herbert LJ, Middleton SI. **An estimate of syphilis incidence in Eastern Europe.** J Glob Health 2 (2012) 10402. 1-7.
7. Kent ME, Romanelli F. **Reexamining syphilis: an update on epidemiology, clinical manifestations, and management.** Ann Pharmacother 42 (2008) 226-236.
8. Manavi K, Young H, McMillan A. **The sensitivity of syphilis assays in detecting different stages of early syphilis.** Int J STD AIDS 17 (2006) 768-771.
9. Muller I, Brade V, Hagedorn HJ, Straube E, Schorner C, Frosch M, Hlobil H, Stanek G, Hunfeld KP. **Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the German infection serology proficiency testing program.** J Clin Microbiol 44 (2006) 1335-1341.
10. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a *Treponema pallidum*-specific IgM enzyme immunoassay and *Treponema pallidum* western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
11. Rigsby P, Ison C, Brierley M, Ballard R, Hagedorn HJ, Lewis DA, Notermans DW, Riis J, Robertson P, Seppälä IJ, Rijpkema S. **Evaluation of two human plasma pools as candidate international standard preparations for syphilitic antibodies.** Biologicals 37 (2009) 245-251.
12. EUROIMMUN AG. Stöcker W, Ehling T. **Vorrichtung und Verfahren zur Untersuchung einer biologischen Probe.** Deutsche Patentanmeldung DE 10 2011 011 795.4 (angemeldet 2011).
13. Stöcker* W, Fauer* H, Krause* C, Barth E, Martinez A. (*EUROIMMUN AG). **Verfahren zur Optimierung der automatischen Fluoreszenzerkennung in der Immundiagnostik.** Deutsche Patentanmeldung (Offenlegungsschrift) DE 10 2006 027 516.0 und WO2007140952 (2006).
14. Sun R, Lai DH, Ren RX, Lian S, Zhang HP. ***Treponema pallidum*-specific antibody expression for the diagnosis of different stages of syphilis.** Chin Med J (Engl) 126 (2013) 206-210.



Liability

The test kit, including original accessories, must only be used in accordance with the intended use. EUROIMMUN accepts no liability for any other use (e.g. non-compliance with the instructions for use and improper use) or for resulting damages.

Technical Support

In case of technical problems you can obtain assistance via the EUROIMMUN website (<https://www.euroimmun.de/en/contact/>).

Additional information

Regulatory information for customers in the European Union: Please observe the obligation to report any serious incidents occurring in connection with this product to the competent authorities and to EUROIMMUN.



